Announcements Trials
Browse Landscape Eligibility

Clinical Trials

1 trials
RecentStart dateEnrollment
MSI-H × Clear all

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Breast Neoplasms 12991Neoplasms 10383Carcinoma, Non-Small-Cell Lung 6796Prostatic Neoplasms 6198Colorectal Neoplasms 5864Lung Neoplasms 5042Multiple Myeloma 3542Pancreatic Neoplasms 3512Neoplasm Metastasis 3480Leukemia, Myeloid, Acute 3469Carcinoma, Hepatocellular 3232Ovarian Neoplasms 3138Melanoma 3120Stomach Neoplasms 3020Lymphoma 2970Head and Neck Neoplasms 2575Recurrence 2528Precursor Cell Lymphoblastic Leukemia-Lymphoma 2485Leukemia 2353Colonic Neoplasms 2317Brain Neoplasms 2293Lymphoma, Non-Hodgkin 2257Rectal Neoplasms 2173Uterine Cervical Neoplasms 2164Glioblastoma 1993Leukemia, Lymphocytic, Chronic, B-Cell 1985Carcinoma, Renal Cell 1897Squamous Cell Carcinoma of Head and Neck 1857Lymphoma, Follicular 1829Esophageal Neoplasms 1786

Interventions

sintilimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements
NCT05890742 2024-03-15

A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Recruiting
360 enrolled
Other solid neoplasm

MSI-H

Data powered by HemOnc (CC BY 4.0) Colophon âš¡